Explore the Agenda
7:00 am Check In, Morning Coffee & Light Refreshments
Bringing ADCs to Earlier Line Oncology Therapies: Showcasing ADC Development Providing Long-Term Benefit to Patients
8:00 am Reviewing the ADC Clinical & Approval Landscape: What Direction are ADCs Heading to Reshape Frontline Oncology Treatments For Patients?
- Reviewing the breast cancer patient treatment landscape: Where do ADCs currently fit in with standard of care treatments and how is this evolving?
- Explaining the physician’s perspective and patient attitudes to ADC treatments given anti-tumor efficacy and toxicity profiles
- Assessing the rise of ADC patient resistance mechanisms and explaining the importance of mechanism and design differentiation to provide long-term patient benefit
8:30 am Spotlighting Enhertu’s Historic HER2-Positive Solid Tumor Agnostic & Metastatic Breast Cancer HER2-Ultralow Approvals
- Breaking down readouts from DESTINY clinical trials which led to tumor-agnostic HER2-positive solid tumor approval
- Outlining DB06 data and results of Enhertu in HER2 ultralow patient populations: what impact does target expression have across tumor types
- Evaluating the impact of Enhertu demonstrating superiority vs. chemotherapy in metastatic breast cancer to advance ADCs towards earlier-line oncology treatments
9:00 am Harnessing ADC Design Strategies for Next-Generation AOCs
- Expanding architecture of linker payload and conjugation modality for AOCs
- Solving the challenges of next generation conjugates using Thiobridge® technology
- Supporting characterization and manufacture of bioconjugates through Abzena’s integrated offering
9:30 am Showcasing Updated Clinical Profile & Sustained Overall Survival Benefit of Belantamab Mafodotin Combination to Understand How ADC MoA Translates to Advancing to Earlier Line Oncology Treatments
- Breaking down the updated clinical profile of belantamab mafodotin combinations from DREAMM-7 trial with sustained overall survival benefit in patients with relapsed or refractory multiple myeloma
- Explaining how multi-modal mechanism of action across payload, immunogenic cell death, and adaptive immune response translates to durable patient response and long-term clinical benefit
- Contextualizing belantamab mafodotin’s ongoing regulatory journey
- Evaluating the journey of ADCs transitioning to earlier-line treatments for oncology patients across tumor types
10:00 am Morning Break & Networking
Discovery Chemistry
Discovery Biology
Preclinical
Translational Medicine
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
Discovery Chemistry
Spotlighting Novel Payload MoAs for Next-Gen ADC Design to Combat Patient Resistance
4 Sessions
Presentation Sneak Peek:
Senior Scientist, PROxAb Shuttle, Merck KGaA
Targeted PROTAC Delivery: Principles of Crafting PROTAC-ADCs & Self-Assembling PROxAb Shuttles
- Summarizing the current technological status of Degrader-ADCs, emphasizing the challenges in their generation
- Introducing the PROxAb Shuttle technology, which has the potential to expedite Degrader-ADC discovery
- Presenting data showcasing the practical application of the PROxAb Shuttle in vivo
Discovery Biology
Preclinical
Translational Medicine
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
1:00 pm Lunch & Networking
Discovery Chemistry
Discovery Biology
Preclinical
Translational Medicine
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
Discovery Chemistry
Approaching ADC Chemistry Innovation with Clinical Differentiation In Mind
4 Sessions
Presentation Sneak Peek:
Senior Scientist, PROxAb Shuttle, Merck KGaA
Targeted PROTAC Delivery: Principles of Crafting PROTAC-ADCs & Self-Assembling PROxAb Shuttles
- Summarizing the current technological status of Degrader-ADCs, emphasizing the challenges in their generation
- Introducing the PROxAb Shuttle technology, which has the potential to expedite Degrader-ADC discovery
- Presenting data showcasing the practical application of the PROxAb Shuttle in vivo
Discovery Biology
Preclinical
Translational Medicine
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
4:00 pm Afternoon Break & Networking
Evaluating Performance of Novel ADC Design & MoA Differentiation to Assess Activity Versus Validated Clinical Successes
5:00 pm Panel Discussion: Delving into Novel Design & Development to Strive for Next-Generation ADCs Providing Long-Term Benefit to Patients
- Evaluating the landscape of ADC therapies: is the risk of innovation now lower than the risk of irrelevancy?
- Assessing hurdles and opportunities to achieve differentiated ADC profiles in crowded ADC payload and target fields
- Delving into novel ADC payloads: what new MoAs are emerging and what has been demonstrated so far?
- Understanding perspectives on the future of ADC development across ADC design, targeting, and precision medicine approaches
5:45 pm Leveraging Novel Conjugation Technology & Enhanced Antibody Targeting to Engineer the Next Generation of ADCs & Targeted Oncology Therapeutics
- Understanding the scope to differentiate ADCs through novel targets and antibody engineering to widen target indications and patient populations
- Leveraging non-natural amino acid conjugation technology to design ADCs with enhanced design and properties
- Incorporating in silico and AI tools to enhance next-generation ADC engineering and desig
6:15 pm Expediting Development of Novel ADCs Through WuXi XDC’s Innovative Technology Platform & Fully Integrated CMC Services
- Exploring WuXiDAR4, WuXi XDC’s proprietary conjugation technology which produces more homogenous ADC compared to the DAR4 ADC generated through random conjugation. This results in enhanced efficacy, improved (PK), and a superior safety profile in clinical trials
- Sharing WuXi XDC’s novel linker and payload-linker, which enables the development of better ADCs with increased stability and a wider therapeutic index
- Showcasing our one-stop discovery service platform, which accelerates the selection of pre-clinical candidates, and our fully integrated CMC service, which reduce the ADC development timeline from DNA to IND filing to just 13-15 months
6:45 pm Unveiling Novel Payload & ADC Design Attributes & Performance for Next Generation ADC Targeting & Tolerability
- Highlighting the drivers for ADC development beyond traditional cytotoxic payloads
- Detailing development and design of more well-tolerated ADCs with improved therapeutic index and defined patient populations
- Showcasing late-stage preclinical development of novel ADC programs preparing for IND applications